Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy.

about

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy.

Item

http://www.wikidata.org/entity/Q45923418

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Outcome of patients treated fo ...... ilure of lenalidomide therapy.

@en

Outcome of patients treated fo ...... ilure of lenalidomide therapy.

@nl

type

Item

label

Outcome of patients treated fo ...... ilure of lenalidomide therapy.

@en

Outcome of patients treated fo ...... ilure of lenalidomide therapy.

@nl

prefLabel

Outcome of patients treated fo ...... ilure of lenalidomide therapy.

@en

Outcome of patients treated fo ...... ilure of lenalidomide therapy.

@nl

P1476

Outcome of patients treated fo ...... ilure of lenalidomide therapy.

@en

P2093

Cecile Bally

http://www.w3.org/2001/XMLSchema#string

Charikleia Kelaidi

http://www.w3.org/2001/XMLSchema#string

Esther Oliva

http://www.w3.org/2001/XMLSchema#string

Katharina Gotze

http://www.w3.org/2001/XMLSchema#string

Lionel Ades

http://www.w3.org/2001/XMLSchema#string

Mary M Sugrue

http://www.w3.org/2001/XMLSchema#string

Mikkael A Sekeres

http://www.w3.org/2001/XMLSchema#string

Najla Al Ali

http://www.w3.org/2001/XMLSchema#string

Norbert Vey

http://www.w3.org/2001/XMLSchema#string

Rami Komrokji

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

International scoring system for evaluating prognosis in myelodysplastic syndromes

Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide.

Efficacy of lenalidomide in myelodysplastic syndromes.

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.

Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies.

P304

81926-81935

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.18477

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Pierre Fenaux

Ulrich Germing

Uwe Platzbecker

P577

2017-06-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29137233

http://www.w3.org/2001/XMLSchema#string

P932

5669859

http://www.w3.org/2001/XMLSchema#string